Corcept Therapeutics Incorporated (0I3Q.L)
USD 73.44
(3.6%)
USD 73.44
(3.6%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 475.89 Million USD | 20.03% |
| 2022 | 396.47 Million USD | 9.92% |
| 2021 | 360.69 Million USD | 3.56% |
| 2020 | 348.29 Million USD | 15.72% |
| 2019 | 300.98 Million USD | 22.33% |
| 2018 | 246.03 Million USD | 58.07% |
| 2017 | 155.64 Million USD | 96.37% |
| 2016 | 79.26 Million USD | 62.01% |
| 2015 | 48.92 Million USD | 90.6% |
| 2014 | 25.66 Million USD | 151.31% |
| 2013 | 10.21 Million USD | 217.6% |
| 2012 | 3.21 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 29 Thousand USD | -86.12% |
| 2008 | 209 Thousand USD | -56.64% |
| 2007 | 482 Thousand USD | 63.95% |
| 2006 | 294 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 144.27 Million USD | 8.05% |
| 2024 Q2 | 161.27 Million USD | 11.78% |
| 2024 Q3 | 179.67 Million USD | 11.41% |
| 2023 Q3 | 121.95 Million USD | 5.01% |
| 2023 Q1 | 104.26 Million USD | 2.65% |
| 2023 FY | 475.89 Million USD | 20.03% |
| 2023 Q2 | 116.14 Million USD | 11.39% |
| 2023 Q4 | 133.52 Million USD | 9.49% |
| 2022 Q3 | 100.38 Million USD | -1.65% |
| 2022 Q1 | 92.43 Million USD | -5.16% |
| 2022 Q4 | 101.57 Million USD | 1.18% |
| 2022 FY | 396.47 Million USD | 9.92% |
| 2022 Q2 | 102.07 Million USD | 10.42% |
| 2021 Q4 | 97.46 Million USD | 2.75% |
| 2021 Q3 | 94.85 Million USD | 5.16% |
| 2021 Q2 | 90.2 Million USD | 15.4% |
| 2021 FY | 360.69 Million USD | 3.56% |
| 2021 Q1 | 78.16 Million USD | -7.47% |
| 2020 FY | 348.29 Million USD | 15.72% |
| 2020 Q3 | 85.11 Million USD | -2.54% |
| 2020 Q2 | 87.33 Million USD | -4.42% |
| 2020 Q1 | 91.36 Million USD | 5.68% |
| 2020 Q4 | 84.48 Million USD | -0.74% |
| 2019 FY | 300.98 Million USD | 22.33% |
| 2019 Q2 | 70.88 Million USD | 11.47% |
| 2019 Q1 | 63.58 Million USD | -2.55% |
| 2019 Q4 | 86.45 Million USD | 8.0% |
| 2019 Q3 | 80.05 Million USD | 12.94% |
| 2018 Q4 | 65.25 Million USD | 3.35% |
| 2018 FY | 246.03 Million USD | 58.07% |
| 2018 Q2 | 61.15 Million USD | 8.27% |
| 2018 Q3 | 63.13 Million USD | 3.24% |
| 2018 Q1 | 56.48 Million USD | 8.37% |
| 2017 Q4 | 52.12 Million USD | 24.74% |
| 2017 Q2 | 34.78 Million USD | 29.05% |
| 2017 Q3 | 41.78 Million USD | 20.13% |
| 2017 FY | 155.64 Million USD | 96.37% |
| 2017 Q1 | 26.95 Million USD | 15.92% |
| 2016 Q1 | 15.65 Million USD | 7.22% |
| 2016 Q2 | 19.29 Million USD | 23.25% |
| 2016 Q3 | 21.05 Million USD | 9.11% |
| 2016 Q4 | 23.25 Million USD | 10.42% |
| 2016 FY | 79.26 Million USD | 62.01% |
| 2015 Q3 | 13 Million USD | 12.92% |
| 2015 Q4 | 14.6 Million USD | 12.29% |
| 2015 Q2 | 11.51 Million USD | 17.52% |
| 2015 FY | 48.92 Million USD | 90.6% |
| 2015 Q1 | 9.8 Million USD | 11.92% |
| 2014 Q2 | 5.63 Million USD | 33.21% |
| 2014 Q3 | 7.04 Million USD | 25.04% |
| 2014 FY | 25.66 Million USD | 151.31% |
| 2014 Q4 | 8.75 Million USD | 24.25% |
| 2014 Q1 | 4.23 Million USD | 4.37% |
| 2013 Q2 | 1.86 Million USD | 10.08% |
| 2013 FY | 10.21 Million USD | 217.6% |
| 2013 Q4 | 4.05 Million USD | 56.28% |
| 2013 Q3 | 2.59 Million USD | 38.87% |
| 2013 Q1 | 1.69 Million USD | 24.96% |
| 2012 Q3 | 1.03 Million USD | 24.67% |
| 2012 Q2 | 827 Thousand USD | 0.0% |
| 2012 FY | 3.21 Million USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | 1.35 Million USD | 31.72% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 100.0% |
| 2009 Q4 | -1000.00 USD | -100.1% |
| 2009 FY | 29 Thousand USD | -86.12% |
| 2009 Q3 | 1.02 Million USD | 16983.33% |
| 2009 Q2 | 6000.00 USD | -75.0% |
| 2009 Q1 | 24 Thousand USD | -83.22% |
| 2008 Q3 | 66 Thousand USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | 209 Thousand USD | -56.64% |
| 2008 Q4 | 143 Thousand USD | 116.67% |
| 2007 Q3 | - USD | -100.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | 482 Thousand USD | 63.95% |
| 2007 Q1 | 108 Thousand USD | 47.95% |
| 2007 Q2 | 374 Thousand USD | 246.3% |
| 2006 Q3 | - USD | -100.0% |
| 2006 Q2 | 100 Thousand USD | -17.36% |
| 2006 Q4 | 73 Thousand USD | 0.0% |
| 2006 Q1 | 121 Thousand USD | 0.0% |
| 2006 FY | 294 Thousand USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -21385.056% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -157480.795% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 658.456% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -2647.815% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 152142.812% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -3116.804% |
| Imunon, Inc. | -720 Thousand USD | 66195.93% |
| Dynavax Technologies Corporation | 182.11 Million USD | -161.312% |
| Editas Medicine, Inc. | -99.52 Million USD | 578.151% |
| FibroGen, Inc. | 128.9 Million USD | -269.185% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 5074.848% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 157160.726% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 74.24% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 56.46% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 9.136% |
| Verastem, Inc. | -62 Thousand USD | 767670.968% |
| Zoetis Inc. | 5.83 Billion USD | 91.843% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 94.471% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 1149.959% |
| Homology Medicines, Inc. | -7.22 Million USD | 6683.124% |
| Nektar Therapeutics | 53.47 Million USD | -789.887% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 163077.397% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 2515.828% |
| Perrigo Company plc | 1.68 Billion USD | 71.68% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -551.312% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 98.206% |
| Illumina, Inc. | 2.74 Billion USD | 82.657% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 96.874% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 90.916% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -4639.036% |
| Waters Corporation | 1.76 Billion USD | 72.979% |
| Biogen Inc. | 7.3 Billion USD | 93.483% |
| Evolus, Inc. | 140.52 Million USD | -238.652% |
| Adicet Bio, Inc. | -6.09 Million USD | 7904.1% |
| bluebird bio, Inc. | -4.03 Million USD | 11908.784% |
| Geron Corporation | -123.5 Million USD | 485.33% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 68.648% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -31.452% |
| Myriad Genetics, Inc. | 476.4 Million USD | 0.106% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 219.333% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 78.06% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 1626.884% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 75.01% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 95.789% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 86.266% |
| OPKO Health, Inc. | 318.12 Million USD | -49.592% |
| Exelixis, Inc. | 1.75 Billion USD | 72.925% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -94.612% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 38.871% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 25.279% |
| Blueprint Medicines Corporation | 236.58 Million USD | -101.152% |
| Insmed Incorporated | 239.63 Million USD | -98.591% |
| TG Therapeutics, Inc. | 219.1 Million USD | -117.196% |
| Incyte Corporation | 3.44 Billion USD | 86.168% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -38.382% |